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a b s t r a c t
Aromatic amino acids are precursors of numerous plant secondary metabolites with diverse biological
functions. Many of these secondary metabolites are already being used as active pharmaceutical or
nutraceutical ingredients, and there are numerous exploratory studies of other compounds with
promising applications. p-Coumaric acid is derived from aromatic amino acids and, besides being a
valuable chemical building block, it serves as precursor for biosynthesis of many secondary metabolites,
such as polyphenols, ﬂavonoids, and some polyketides.
Here we developed a p-coumaric acid-overproducing Saccharomyces cerevisiae platform strain. First,
we reduced by-product formation by knocking out phenylpyruvate decarboxylase ARO10 and pyruvate
decarboxylase PDC5. Second, different versions of feedback-resistant DAHP synthase and chorismate
mutase were overexpressed. Finally, we identiﬁed shikimate kinase as another important ﬂux-
controlling step in the aromatic amino acid pathway by overexpressing enzymes from Escherichia coli,
homologous to the pentafunctional enzyme Aro1p and to the bifunctional chorismate synthase-ﬂavin
reductase Aro2p. The highest titer of p-coumaric acid of 1.9370.26 g L1 was obtained, when
overexpressing tyrosine ammonia-lyase TAL from Flavobacterium johnsoniaeu, DAHP synthase ARO4K229L,
chorismate mutase ARO7G141S and E. coli shikimate kinase II (aroL) in Δpdc5Δaro10 strain background. To
our knowledge this is the highest reported titer of an aromatic compound produced by yeast.
The developed S. cerevisiae strain represents an attractive platform host for production of p-
coumaric-acid derived secondary metabolites, such as ﬂavonoids, polyphenols, and polyketides.
& 2015 International Metabolic Engineering Society Published by Elsevier Inc. On behalf of International
Metabolic Engineering Society. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Aromatic amino acids are precursors of many secondary
metabolites produced in plants, where they have a key role in
the plant development, adaptation and defense mechanisms
(Maeda and Dudareva, 2012; Perez-Gregorio et al., 2014). Among
the plant secondary metabolites many alkaloids, ﬂavonoids, tan-
nins and lignins ﬁnd applications as nutraceutical and pharma-
ceutical ingredients (Scotti, 2012). Exploratory research of this
type of compounds shows promising results (Winkel-Shirley,
2001; Hawkins and Smolke, 2008; Bhan et al., 2013; Leonard
et al., 2009), but the limiting factor for a wider use of these
secondary metabolites is the lack of efﬁcient extraction systems
from plants, or a competent microbial biosynthetic alternative that
can produce these compounds in high yields (Santos et al., 2011).
There is therefore much interest in developing a microbial cell
factory platform that can be used for production of secondary
metabolites derived from aromatic amino acids. As the biosynth-
esis of many plant secondary metabolites involves P450 enzymes,
which are often difﬁcult to express in bacteria, the yeast Sacchar-
omyces cerevisiae is well suited as a cell factory platform for
production of these products. Since many of the ﬂavonoids are
intended for nutraceutical applications, using S. cerevisiae as the
host may be a further advantage due to the long history of its
application in food and beverage production (Krivoruchko et al.,
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2011; Siddiqui et al., 2012) Furthermore, S. cerevisiae has proven
well amenable for genetic engineering and industrial-scale fer-
mentation and is currently used for production of active pharma-
ceutical ingredients, dietary supplements, chemicals and fuels
(Hong and Nielsen, 2012; Nielsen et al., 2013; Borodina and
Nielsen, 2014; Li and Borodina, 2015; Borodina et al., 2015).
In order to enable efﬁcient production of secondary metabolites
derived from aromatic amino acids it is necessary to optimize
aromatic amino acid biosynthesis. S. cerevisiae has been metabolically
engineered for improved production of aromatic amino acids through
the elimination of feedback inhibition of key enzymes and elimination
of by-product formation. Luttik et al. (2008) explored the use of
mutated DAHP synthase ARO4 and chorismate mutase ARO7 to avoid
feedback inhibition and got an increment of 200-fold of aromatic
compounds in comparison to the reference strain. Furthermore,
through expression of heterologous pathways, it has been possible
to produce secondary metabolites derived from aromatic amino acids.
Thus, Koopman et al. (2012) produced the ﬂavonoid naringenin from
glucose using a background strain with a triple knockout of the most
active phenylpyruvate decarboxylases, which prevented formation of
the by-product phenylethanol, and overexpressing feedback-resistant
DAHP synthase and chorismate mutase.
Escherichia coli and S. cerevisiae have been extensively engineered
in order to obtain ﬂavonoid-producing cell factories. Among the
ﬂavonoids produced in E. coli from glucose are naringenin, pinocem-
brin, and kaempferol 3‑O‑rhamnoside, with titers of 84 mg L1,
40 mg L1, and 57 mg L1, respectively (Santos et al., 2011; Wu et
al., 2014; Yang et al., 2014). Several other ﬂavonoids were produced
by supplementing the broth with intermediate compounds, e.g.,
pinocembrin (429 mg L1), naringenin (119 mg L1), eriodictyol
(52 mg L1), quercetin (23.78 mg L1), and resveratrol (2.3 g L1)
(Leonard et al., 2007; Pandey and Sohng, 2013; Lim et al., 2011).
Flavonoids, such as resveratrol (0.31 mg L1), genistein (7.7 mg L1),
kaempferol (4.6 mg L1), and quercetin (0.38 mg L1), have been
produced by engineered S. cerevisiae, when supplemented with
naringenin (Trantas et al., 2009). Using glucose as carbon source,
Koopman et al. (2012) produced 102 mg L1 of naringenin. Jendresen
et al. (2015) has reported several novel highly active tyrosine
ammonia-lyases and shown their activity in E. coli, Lactococcus lactis
and S. cerevisiae. These examples prove the potential of E. coli and
S. cerevisiae for ﬂavonoids production, but also evidence the need
for development of a platform strain capable of high-level production
of aromatic metabolites, e.g. p-Coumaric acid from which
many secondary metabolites are derived (Santos et al., 2011). We
therefore here developed a S. cerevisiae strain that overproduces
p-coumaric acid, and besides representing a starting point for
further development of a process for commercial p-coumaric
acid, we believe this strain can be used as a platform strain for
production of ﬂavonoids and other coumaric-acid derived secondary
metabolites.
2. Materials and methods
2.1. Plasmids and strains construction
The background strain for this research was S. cerevisiae CEN.
PK102-5B. Cloning was carried out using E. coli strain DH5α. All
the fragments used for overexpression of genes were ampliﬁed by
PCR using primers and templates as described in Supplementary
Tables 1 and 2. The fragment encoding chorismate mutase from C.
guilliermondii was identiﬁed through BLAST search, by comparing
the full amino acids sequence of Aro7p from S. cerevisiae against C.
guilliermondii protein sequences in GenBank. Homology of 60%
was found between Aro7p from S. cerevisiae and the hypothetical
protein PGUG_00476 from C. guilliermondii (Genbank accession
number: XM_001487049.1).
Tyrosine ammonia-lyase TAL from F. johnsoniaeu was as
described before (Jendresen et al., 2015). The ampliﬁed products
were cloned along with strong constitutive promoters into Easy-
Clone integrative plasmids by USER cloning (Jensen et al., 2014).
The clones with correct inserts were conﬁrmed by sequencing. The
list of the constructed vectors can be found in Table 1 and the
details on the cloning are given in Supplementary Table 3.
Transformation of yeast cells was carried out by the lithium
acetate method (Gietz et al., 2002). The strains were selected on
synthetic drop-out medium (Sigma-Aldrich), selecting for URA, HIS
and LEU markers. The yeast strains constructed in this study are
listed in Table 1.
The mutant genes, scARO4fbr (K229L), scARO7fbr (G141S), ecar-
oGfbr1 (L175D) and ecaroGfbr2 (S180F), were constructed by site-
directed mutagenesis method (Zheng et al., 2004), using primers
and templates described in Supplementary Tables 1 and 3. The
ARO4, ARO7 and aroG wild-type genes were ampliﬁed from the
genomic DNA of S. cerevisiae and E. coli NST 74. The DNA fragments
were gel-puriﬁed and cloned into vector pESC-URA-ccdB-USER or
pESC-HIS-ccdB-USER, the derived plasmids pCfB761, pCfB775,
pCfB1075 and pCfB1076 were conﬁrmed by DNA sequencing.
These plasmids were used as the templates for site-directed
mutagenesis reactions. The complementary primers with nucleo-
tide substitutions for mutagenesis were designed for each muta-
tion according to the guidelines stated by Zheng et al., 2004. The
reactions were incubated with DpnI for 1 h before transformation
into competent DH5α E. coli cells, the strains were grown over-
night on LB agar (Amp) plates at 37 1C. Colonies were then
selected, and plasmid DNA was extracted and sequenced over
the region of the mutation. Successful mutants were veriﬁed by
DNA sequencing and then re-cloned into the integrative expres-
sion vectors (Supplementary Tables 2 and 3).
2.2. Deletions of ARO10 and PDC5
The double knockout strain Δaro10Δpdc5 was constructed by
an iterative replacement of the targeted genes with the URA3
cassette in the strain CEN.PK102-5B by bi-partite method (Erdeniz
et al., 1997). The knockout fragments were transformed into S.
cerevisiae and transformants were selected on SC-Ura yeast syn-
thetic drop-out media. The knockouts were conﬁrmed by PCR on
genomic DNA preparations. The URA3 marker was looped-out via
direct repeats by growing the yeast on 5-ﬂuoroorotic acid (5-FOA)
plates, and the second gene was knocked-out in the same way and
the URA3 marker was removed again.
For the single knockout strains (Δaro10 and Δpdc5), the target
genes were replaced by a LEU2 cassette in the strain CEN.PK102-
5B. The knockout fragments were transformed into S. cerevisiae
and transformants were selected on SC-Leu yeast synthetic drop-
out media. The knockouts were conﬁrmed by PCR on genomic
DNA preparations.
The gene fragments, carrying the upstream and downstream
fragments of the marker cassettes URA3 and LEU2 and of the
targeted genes ARO10 and PDC5, were generated by PCR ampliﬁca-
tion using the method developed by Reid et al. (2002). Primers and
templates used for targeting the genes are indicated in Supple-
mentary Tables 1 and 2. The upstream fragments of the targeted
genes (PDC5_UP or ARO10_UP), the downstream fragments of the
targeted genes (PDC5_DOWN or ARO10_DOWN), the upstream
and downstream fragment of the markers (2/3_URA3_UP,
2/3_URA3_DOWN, for the double knockout strain and
2/3_LEU2_UP and 2/3_LEU2_DOWN for the single knockout strain
construction) from Kluyveromyces lactis were ampliﬁed using
primers described in Supplementary Table 1. To generate a
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Table 1
Plasmids and strains used in this study.
Plasmid ID Genotype Source
Parental plasmids
pCfB0054 Episomal replication vector, pESC, HIS, PTEF1-TADH1, PPGK1-TCYC1 Jensen et al.
(2014)
pCfB0055 Episomal replication vector, pESC, HIS, PTEF1-TADH1, PPGK1-TCYC1 Jensen et al.
(2014)
pCfB255 Integrative plasmid, pX-2-loxP, klURA3, PTEF1-TADH1, PPGK1-TCYC1 Jensen et al.
(2014)
pCfB257 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1-TADH1, PPGK1-PPGK1 Jensen et al.
(2014)
pCfB258 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-TADH1, PPGK1-TCYC1 Jensen et al.
(2014)
Plasmids used for directed mutagenesis
pCfB744 Episomal replication vector, pESC, URA, PTEF1-scARO7-TADH1 This study
pCfB745 Episomal replication vector, pESC, HIS, PTEF1-scARO4-TADH1 This study
pCfB761 Episomal replication vector, pESC, URA, PTEF1-scARO7fbr-TADH1 This study
pCfB775 Episomal replication vector, pESC, HIS, PTEF1-scARO4fbr-TADH1 This study
PCfB1074 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1-ecAroG-TADH1 This study
PCfB1075 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1- ecaroGfbr1-TADH1 This study
PCfB1076 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1- ecaroGfbr2-TADH1 This study
Integrative plasmids
pCfB826 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-scARO7fbr-TADH1, PPGK1-
scARO4fbr-TCYC1
This study
pCfB827 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-scARO7fbr-TADH1, PPGK1-
ecaroFfbr-TCYC1
This study
pCfB830 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-cgARO7-TADH1, PPGK1-scARO4fbr-
TCYC1
This study
pCfB831 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-cgARO7-TADH1, PPGK1-ecaroFfbr-
TCYC1
This study
pCfB1077 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-scARO7fbr-TADH1, PPGK1-
ecaroGfbr1-TCYC1
This study
pCfB1078 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-cgARO7-TADH1, PPGK1-ecaroGfbr1-
TCYC1
This study
pCfB1080 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-scARO7fbr-TADH1, PPGK1-
ecaroGfbr2-TCYC1
This study
pCfB1081 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-cgARO7-TADH1, PPGK1-ecaroGfbr2-
TCYC1
This study
pCfB1221 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1-scTYR1-TADH1 This study
pCfB1226 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-ectyrAfbr-TADH1, PPGK1-
scARO4fbr-TCYC1
This study
pCfB1227 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-ectyrAfbr-TADH1, PPGK1- ecaroFfbr-
TCYC1
This study
pCfB1228 Integrative plasmid, pX-4-loxP, spHIS5, PTEF1-ectyrAfbr-TADH1, PPGK1-
ecaroGfbr1-TCYC1
This study
pCfB1964 Integrative plasmid, pX-2-loxP, KlURA3, PTEF1-fjTAL-TADH1 This study
pCfB2733 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1- scARO1-TADH1, PPGK1- scARO2-
TCYC1
This study
pCfB2739 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1-ecaroB-TADH1 This study
pCfB2741 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1-ecaroE-TADH1 This study
pCfB2742 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1-ecydiB-TADH1 This study
pCfB2743 Integrative plasmid, pX-3-loxP, klLEU2, PPGK1-ecaroK-TCYC1 This study
pCfB2745 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1-ecaroA-TADH1 This study
pCfB2746 Integrative plasmid, pX-3-loxP, klLEU2, PPGK1-ecaroD-TCYC1 This study
pCfB2747 Integrative plasmid, pX-3-loxP, klLEU2, PPGK1-ecaroL-TCYC1 This study
pCfB2749 Integrative plasmid, pX-3-loxP, klLEU2, PPGK1-ecaroC-TCYC1 This study
pCfB2740 Integrative plasmid, pX-3-loxP, klLEU2, PTEF1-scARO1-TADH1 This study
pCfB2748 Integrative plasmid, pX-3-loxP, klLEU2, PPGK1-scARO2-TCYC1 This study
Parent and template strains
Strain ID Strain Source
ST10 S. cerevisiae CEN.PK102-5B (MATa ura3-52 his3 Δ 1 leu2-3/112 MAL2-8c
SUC2)
Peter Kötter
ST700 E. coli NST 74 (ATCC 31884) ATCC
ST679 C. guilliermondii (ATCC 6260) ATCC
Knockout strains
Strain ID Parent strain Characteristics Source
ST4034 ST10 MATa aro10Δ: LEU2 This study
ST3532 ST10 MATa pdc5Δ: LEU2 This study
ST691 ST10 MATa aro10Δ pdc5Δ This study
Strains transformed with integrative
plasmids
Strain ID Parent strain Integrated plasmids Source
ST4068 ST10 pCfB1964, pCfB257,
pCfB258
This study
ST4069 ST10 pCfB255, pCfB257, pCfB258 This study
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complete gene targeting substrate, the upstream fragments
(PDC5_UP or ARO10_UP), were fused to the 2/3 upstream fragment
of the markers (2/3_URA3_UP for the double knockout and
2/3_LEU2_UP for the single knockout), in the same way, the
downstream fragments were fused to the downstream fragment
of the markers (2/3_URA3_DOWN for the double knockout and
2/3_LEU2_DOWN for the single knockout). The two fusion PCR
fragments per targeted gene were transformed simultaneously
into the S. cerevisiae strain and selected in SC-Ura or Sc-Leu
medium according to the selection marker. The correct transfor-
mants were conﬁrmed by PCR, using primers described in
Supplementary Table 1.
2.3. Media and cultivations
Synthetic complete (SC) medium as well as drop-out media
(SC-Ura, SC-Leu, SC-His) and agar plates were prepared using pre-
mixed drop-out powders from Sigma-Aldrich. Synthetic fed-batch
medium for S. cerevisiae M-Sc.syn-1000 (FIT) was purchased from
M2P labs GmbH (Germany). The medium was supplemented with
the supplied vitamins solution (ﬁnal 1% v/v) and the enzyme mix
(ﬁnal concentration 0.5% v/v) immediately prior to use.
At least six single colonies originating from independent
transformants were inoculated in 0.5 ml drop-out SC liquid med-
ium without uracil, histidine, and/or leucine in 96-deep well
Table 1 (continued )
Plasmid ID Genotype Source
ST4072 ST4034 pCfB1964, pCfB258 This study
ST4073 ST4034 pCfB255, pCfB258 This study
ST4070 ST3532 pCfB1964 This study
ST4071 ST3532 pCfB255 This study
ST4048 ST691 pCfB1964, pCfB257,
pCfB258
This study
ST4050 ST691 pCfB255, pCfB257, pCfB258 This study
ST2645 ST691 pCfB1964, pCfB257,
pCfB826
This study
ST4040 ST691 pCfB1964, pCfB1221,
pCfB826
This study
ST4049 ST691 pCfB1964, pCfB257,
pCfB830
This study
ST4044 ST691 pCfB1964, pCfB1221,
pCfB830
This study
ST4038 ST691 pCfB1964, pCfB257,
pCfB1226
This study
ST4041 ST691 pCfB1964, pCfB1221,
pCfB827
This study
ST4051 ST691 pCfB1964, pCfB257,
pCfB827
This study
ST4045 ST691 pCfB1964, pCfB1221,
pCfB831
This study
ST4052 ST691 pCfB1964, pCfB257, pCfB831 This study
ST4037 ST691 pCfB1964, pCfB257,
pCfB1227
This study
ST4053 ST691 pCfB1964, pCfB257,
pCfB1077
This study
ST4042 ST691 pCfB1964, pCfB1221,
pCfB1077
This study
ST4054 ST691 pCfB1964, pCfB257,
pCfB1078
This study
ST4046 ST691 pCfB1964, pCfB1221,
pCfB1078
This study
ST4039 ST691 pCfB1964, pCfB257,
pCfB1228
This study
ST4055 ST691 pCfB1964, pCfB257,
pCfB1080
This study
ST4043 ST691 pCfB1964, pCfB1221,
pCfB1080
This study
ST4056 ST691 pCfB1964, pCfB257,
pCfB1081
This study
ST4047 ST691 pCfB1964, pCfB1221,
pCfB1081
This study
ST3213 ST691 pCfB1964, pCfB826 This study
ST4057 ST3213 pCfB2739 This study
ST4065 ST3213 pCfB2746 This study
ST4062 ST3213 pCfB2741 This study
ST4063 ST3213 pCfB2742 This study
ST4066 ST3213 pCfB2743 This study
ST4058 ST3213 pCfB2747 This study
ST4064 ST3213 pCfB2745 This study
ST4060 ST3213 pCfB2749 This study
ST4067 ST3213 pCfB2733 This study
ST4061 ST3213 pCfB2740 This study
ST4059 ST3213 pCfB2748 This study
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microtiter plates with air-penetrable lid (EnzyScreen, NL). The
plates were incubated at 30 1C with 250 rpm agitation at 5 cm
orbit cast overnight. 50 ml of the overnight cultures were used to
inoculate 0.5 ml synthetic fed-batch medium in a 96-deep well
plate. Fermentation was carried out for 72 h at the same condi-
tions as above.
At the end of the cultivation OD600 was measured as following:
10 ml of the sample was mixed with 190 ml water and absorbance was
measured at 600 nmwavelength in microplate reader BioTek Synergy
MX (BioTek). The culture broth was spun down and the supernatant
was analyzed for p-coumaric acid concentration using HPLC.
2.4. Quantiﬁcation of p-coumaric acid
Quantiﬁcation of p-coumaric acid was performed on HPLC
(Thermo), equipped with a Discovery HS F5 150 mm2.1 mm
column (particle size 3 mm). Samples were analyzed using a
gradient method with two solvents: 10 mM ammonium formate
pH 3.0 (A) and acetonitrile (B) at 1.5 ml min1. The program
started with 5% of solvent B (0–0.5 min), after which its fraction
was increased linearly from 5% to 60% (0.5–7.0 min) and main-
tained at 60% for 2.5 min (7.0–9.5 min). Then the fraction of
solvent B was decreased back to 5% (9.5–9.6 min) and remained
at 5% until the end (9.6–12 min). p-Coumaric acid was detected by
absorbance at 277 nm and the peak (retention time 4.7 min) area
was integrated with Chromeleon 7 and used for quantiﬁcation by
ﬁtting with a standard curve. For all the strains at least three
biological replicates were analyzed.
3. Results
3.1. Deletion of phenylpyruvate and pyruvate decarboxylases
In order to avoid production of aromatic alcohols and direct the
pathway ﬂux to aromatic amino acids, we performed single
knockouts of ARO10 (phenylpyruvate decarboxylase), PDC5 (pyr-
uvate decarboxylase), and a double knock out of ARO10 and PDC5.
Fig. 1. Schematic representation of the engineered p-coumaric acid production pathway in S. cerevisiae. E4P: erythrose 4-phosphate, PEP: phosphoenolpyruvate, DAHP:
3-deoxy-D-arabino-heptulosonic acid 7-phosphate, DHQ: 3-dehydroquinate, DHS: 3-dehydro-shikimate, SHIK: shikimate, SHP: shikimate-3-phosphate, EP3P: 5-enolpyr-
uvylshikimate-3-phosphate, PPA: prephenate, PPY: phenylpyruvate, HPP: para-hydroxy-phenylpyruvate, PAC: phenylacetaldehyde, pPAC: para-hydroxy-acetaldehyde,
L-PHE: L-phenylalanine, L-TYR: L-tyrosine, p-CA: p-coumaric acid, TAL: tyrosine ammonia-lyase. The star key indicates overexpressed enzymes; enzymes in gray boxes
represent knockouts, “fbr” indicates feedback-resistant.
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Furthermore, a tyrosine ammonia-lyase TAL from F. johnsoniae was
overexpressed in these strains in order to produce p-coumaric acid
(Jensen et al., 2014) (Fig. 1).
The reference strain without deletions was able to produce
0.2470.03 g L1 of p-coumaric acid (Fig. 2). The strain with the
single deletion of PDC5 produced 0.3070.09 g L1 of p-coumaric
acid, while the strain carrying the knockout of ARO10 produced
0.2970.04 g L1. The highest production (0.5570.13 g L1) was
obtained in the strain with the double knockout of ARO10 and
PDC5.
3.2. Effect of the elimination of the feedback inhibition of DAHP
synthase and chorismate mutase on p-coumaric acid production
The enzymes DAHP synthase and chorismate mutase from
the aromatic amino acids pathway are feedback-inhibited by
L-tyrosine and L-phenylalanine (Hartmann et al., 2003; Luttik
et al., 2008). In order to enhance the activity of these enzymes,
we overexpressed feedback-resistant variants of DAHP synthase
and chorismate mutase in the Δaro10Δpdc5 strain. For this we
selected 4 variants of DAHP synthase, a mutated feedback-
resistant ARO4K229L from S. cerevisiae, an aroF from E. coli NST 74
(ATCC 31884) and two mutant variants of aroG, also from E. coli,
which were constructed through replacement of the residues
L175D and S180F of the hydrophobic domain. For chorismate
mutase, there were selected a mutated feedback-resistant
ARO7G141S from S. cerevisiae, a naturally feedback-resistant chor-
ismate mutase from C. guilliermonii and tyrA from the E. coli strain
NST 74 (ATCC 31884) (Tribe, 1987). The chorismate mutase from C.
guilliernondii had been reported as non-feedback inhibited (Bode
and Birnbaum, 1991). The variants of chorismate mutase from S.
cerevisiae and C. guilliermondii were complemented with prephe-
nate dehydrogenase TYR1 from S. cerevisiae in order to get
equivalent overexpressions to the bifunctional chorismate
mutase-prephenate dehydrogenase TyrA from E. coli NST 74 (ATCC
31884). The mutations were selected from previous studies, where
they had been reported as feedback-insensitive mutations: the
mutations in ARO4 and ARO7 were reported by Luttik et al. (2008),
the mutation of aroG (L175D) was reported by Hu et al. (2003) and
the mutation of aroG (S180F) was reported by Ger et al. (1994).
All the strains overexpressing DAHP synthase and chorismate
mutase were evaluated for their ability to produce p-coumaric acid
and a two-way ANOVA was conducted to analyze the effect of DAHP
synthases and chorismate mutases. The p-coumaric acid production
was normally distributed for all the combinations of DAHP synthases
and chorismate mutases as assessed by a Shapiro–Wilk's test (p-
Value40.05). The results showed that the overexpression of chor-
ismate mutase alone did not have a signiﬁcant effect on the
production of p-coumaric acid (p-Value 0.399), while the overexpres-
sion of DAHP synthase and the combined overexpression of DAHP
synthase and chorismate mutase had a signiﬁcant effect on the
production of the compound (p-Values 0.010 and 0.0005 correspond-
ingly) (Supplementary Tables 4 and 5).
From the strains overexpressing scARO4fbr, the best combina-
tion was obtained, when overexpressing at the same time scAR-
O7fbr, for the strains overexpressing ecaroF the best producer was
obtained in combination with cgARO7fbr. Although the two resi-
dues replaced in the aroG strains are located in the same region,
the p-coumaric acid production after the overexpression of the
mutated AroG enzymes was different. The replacement L175D
seems to generate a more active AroG, since two of the strains
carrying this mutation (ecaroGfbr1-ectyrA and ecaroGfbr1-cgARO7)
had production of over 0.9 g L1 in contrast to the strains with the
replacement S180F, where the titer did not exceed 0.8 g L1. It was
not possible to see a general trend of the effect of Tyr1p in the
production of p-coumaric acid, but in 4 of the 8 strains over-
expressing this enzyme a negative effect was observed (Fig. 3).
The overexpression of DAHP synthase and chorismate mutase
mostly had a positive effect on production of p-coumaric acid,
however there were some exceptions: scARO4-cgARO7, scARO4-
ectyrA, ecaroG-ARO7 and ecaroG-scARO7-scTYR1 all resulted in the
same or lower titer than in the reference strain.
3.3. p-Coumaric acid production after overexpression of ARO1 and
ARO2 from S. cerevisiae and their analogous from E. coli
In S. cerevisiae, the ﬁve steps to synthetize the aromatic
intermediate compound 5-enolpyruvylshikimate-3-phosphate
(EPSP) from DAHP are catalyzed by the pentafunctional enzyme
Aro1p, while in other organisms such as plants and bacteria each
step is performed by monofunctional enzymes (Fig. 1). In order to
ﬁnd ﬂux-controlling steps in this common branch of the aromatic
amino acid pathway, analogous enzymes to Aro1p and Aro2p from
E. coli were overexpressed in S. cerevisiae. Strains overexpressing
ARO1 and ARO2 from S. cerevisiae were also constructed with the
purpose of making a comparative analysis between the strains
overexpressing enzymes from E. coli and S. cerevisiae. The back-
ground strain for this experiment was the strain ST3213
(aro10Δpdc5Δ ARO4K229L ARO7G141S). The control strain for this
experiment was the strain ST3213 transformed with the empty
integrative plasmid pCfB257 instead of plasmids carrying over-
expression cassettes for ARO1, ARO2 or their analogous.
The overexpression of the monofunctional enzymes from E. coli
had a positive effect on the p-coumaric acid production; the only
exception was the overexpression of shikimate kinase AroK (Fig. 4A).
Fig. 3. Production of p-coumaric acid upon overexpression of feedback inhibition-
resistant DAHP synthase and chorismate mutase in strains with overexpression of
FjTAL and deletion of PDC5 and ARO10.
Fig. 2. Effect of knockouts of ARO10 and PDC5 on p-coumaric acid production in
strains overexpressing tyrosine-ammonia lyase FjTAL from F. johnsoniaeu.
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The strains overexpressing dehydroquinate synthase (AroB), shiki-
mate dehydrogenase (YdiB), EPSP synthase (AroA) or shikimate
kinase (AroL) produced more than 1.6 g L1 of p-coumaric acid.
The strain with the highest improvement was the strain overexpres-
sing the isoenzyme of shikimate kinase AroL, producing
1.9370.26 g L1 of p-coumaric acid.
Overexpression of the pentafunctional enzyme Aro1p and the
bifunctional chorismate synthase-ﬂavin reductase Aro2p from
S. cerevisiae had a positive effect in the p-coumaric acid production.
The strain overexpressing Aro1p produced 1.6870.19 g L1 of
p-coumaric acid, the strain overexpressing Aro2p produced
1.4070.12 g L1, and the simultaneous overexpression of Aro1p
and Aro2p increased the production of p-coumaric acid to
1.7170.12 g L1. The production of p-coumaric acid was very similar
between the strain overexpressing Aro1p and the strain overexpres-
sing Aro1p and Aro2p simultaneously. None of the strains expressing
native versions of Aro1p and Aro2p produced more p-coumaric acid
than the strain overexpressing AroL from E. coli (Fig. 4B).
4. Discussion
This study describes engineering of S. cerevisiae for production
of p-coumaric acid from glucose, leading to a ﬁnal production titer
of 1.9370.26 g L1 on feed-in-time medium in deep-well plates,
which represents a 7.9-fold improvement in comparison to the
non-optimized strain. The optimized strain also produced
1.89 g L1 p-coumaric acid in controlled fed-batch fermentation
on mineral medium (Supplementary Fig. 1). To the best of our
knowledge, this is the highest titer of de novo production of an
aromatic compound reported for S. cerevisiae. There are studies of
ﬂavonoids production from glucose in E. coli and S. cerevisiae;
however none of them has p-coumaric acid as the ﬁnal product.
Some studies reported the accumulation of p-coumaric acid in
parallel to the production of other aromatic compounds. In E. coli,
Santos et al. (2011) and Wu et al. (2014) reported accumulation of
p-coumaric acid to 79 and 70 mg L1, respectively, when they
were producing 84 and 101 mg L1 of naringenin. In S. cerevisiae,
Koopman et al. (2012) reported around 61 mg L1 of accumulated
p-coumaric acid, when they were producing 65 mg L1 of narin-
genin in bioreactors.
The single knockouts of PDC5 and ARO10 had a positive effect
on the production p-coumaric acid. The PDC5 strain was auxo-
trophic for histidine, and the effect of the PDC5 knockout in
comparison to ARO10 may be different in a prototrophic strain.
The simultaneous deletions lead a 2-folds improvement in com-
parison to the reference strain (Fig. 2).This was expected as
deletion of the two genes had been previously reported to improve
production of some other tyrosine- and phenylalanine-derived
compounds, i.e., naringenin (Koopman et al., 2012)
The results obtained from the 2-factor Anova showed that
overexpression of chorismate mutase alone did not have a statis-
tically signiﬁcant effect on production of p-coumaric acid. This is
consistent with results obtained by Luttik et al. (2008), where
overexpression of a native or a feedback resistant Aro7 did not
have signiﬁcant impact on the production of the aromatic fusel
alcohols, unless Aro4 was overexpressed as well.
Besides Aro4p and Aro7p that have been widely reported as
feedback controlled enzymes, there must be other enzymes limit-
ing the production of aromatic amino acids. To this end, we
showed that the activity of the pentafunctional enzyme Aro1p in
S. cerevisiae is also limiting for the biosynthesis of chorismate.
With exception of the strain overexpressing AroK, all the strains
overexpressing the Aro1p and Aro2p analogous enzymes from E.
coli had a higher production of p-coumaric acid (Fig. 4A). These
results show that these enzymes also exhibit ﬂux control and
further improvements can be obtained through the overexpres-
sion of heterologous enzymes with higher activity than Aro1p and
Aro2p from S. cerevisiae.
The strain overexpressing AroL from E. coli had the highest
production of p-coumaric acid, indicating that conversion of shiki-
mate to shikimate-3-phosphate has the highest ﬂux control of these
ﬁve steps. These results are supported by the observation from Luttik
et al. (2008), where they reported accumulation of shikimate in the
culture supernatants after overexpression of scAro4fbr in S. cerevisiae.
Previous studies in E. coli also reported increased ﬂux of intermediate
compounds to L-tyrosine, when shikimate kinase II was overex-
pressed (Takai et al., 2005; Juminaga et al., 2012).
The overexpression of AroK did not increase the production of
p-coumaric acid in the constructed strain. This may be due to the
low afﬁnity of AroK to shikimate, i.e. the Km for shikimate of AroK
is more than 20 mM whereas the Km of AroL is only 0.2 mM
(DeFeyter and Pittard, 1986). The contribution of AroK to the
shikimate kinase activity in E. coli is therefore minimal (DeFeyter
and Pittard, 1986) and its overexpression did not have a signiﬁcant
effect in p-coumaric acid production in E. coli. Previously there was
not detected any feedback inhibition of AroL or AroK by aromatic
amino acids, chorismic acid or prephenic acid (DeFeyter and
Pittard, 1986). Overexpression of the pentafunctional protein
(Aro1p) and the bifunctional chorismate synthase-ﬂavin reductase
(Aro2p) from S. cerevisiae had a positive effect on the production of
p-coumaric acid, though the titer was still lower than of the strain
overexpressing AroL alone.
The p-coumaric acid overproducing strain that we describe can
be further engineered to include overproduction of malonyl-CoA, a
common precursor for biosynthesis of polyphenols and ﬂavonoids.
It has been previously shown that increasing malonyl-CoA supply
improves production of naringenin (Koopman et al., 2012),
Fig. 4. Production of p-coumaric acid upon overexpression of ARO1 and ARO2 from
S. cerevisiae and their analogous from E. coli along with overexpression of
ARO4K229L, ARO7G141S, FjTAL and knockouts of ARO10 and PDC5. (A) Genes from E.
coli; aroB: 3-dehydroquinate synthase, aroD: 3-dehydroquinate dehydratase, aroE:
shikimate dehydrogenase, ydiB: shikimate dehydrogenase – quinate dehydrogen-
ase, arok: shikimate kinase I, aroL: shikimate kinase II, aroA: EPSP synthase, aroC:
chorismate synthase. (B) Genes from S. cerevisiae; ARO1: pentafunctional enzyme,
ARO2: bifunctional chorismate synthase and ﬂavin reductase. Control strain ST2645
(FjTAL, aro10Δpdc5Δ, ARO4K229L, ARO7G141S).
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ﬂavonone (Leonard et al., 2007), and 7-O-methyl aromadendrin
(Malla et al., 2012). Increased ﬂux towards malonyl-CoA can be
achieved by overexpression of deregulated acetyl-CoA carboxylase
(Shi et al., 2014) and by further increase of acetyl-CoA biosynthesis
as described previously (Krivoruchko et al., 2015).
In conclusion, we describe metabolic engineering strategies that
lead towards a platform yeast strain, producing high levels of
p-coumaric acid, which besides being a product of commercial
interest by itself, also serves as an intermediate compound for
aromatic secondary metabolites. We also demonstrate that hetero-
logous expression of tyrosine-ammonia lyase TAL is well suitable for
evaluation of metabolic engineering targets for improving the ﬂux
through the aromatic amino acid biosynthetic pathway. Through
combination of several different strategies we improved the pro-
duction of p-coumaric acid 7.9-fold, and we are therefore conﬁdent
that our strain represents a good platform stain for production of
p-coumaric acid derived secondary metabolites by S. cerevisiae.
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